Payment overview · 2025
General Payments
$1,141.61
49 reported records · 14 companies
Healthcare provider profile · identity verified
Robert Joseph Edwards, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ALEXANDER CITY, AL · NPI 1659662575
Verified facts
What the public records show
CMS Open Payments records show Robert Joseph Edwards, M.D. received $1,141.61 in general payments during 2025 across 49 reported records.
ACADIA Pharmaceuticals Inc accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid, Ozempic.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Nuplazid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $261.24 | 22.9% | 14 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $230.91 | 20.2% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $135.30 | 11.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.97 | 8.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.41 | 7.0% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.02 | 6.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.41 | 4.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $49.51 | 4.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $37.68 | 3.3% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $27.33 | 2.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $23.70 | 2.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.47 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.86 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.80 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,132.53 | 48 |
| Education | $9.08 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $261.24 | 14 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $230.91 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $135.30 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $101.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.02 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $65.82 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $52.74 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $50.41 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.51 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| INPEN SMART INSULIN DELIVERY SYSTEM Normalized: inpen smart insulin delivery system |
Device | Medtronic, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 298 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 108 |
| Trazodone Hcl | Trazodone Hcl | 201 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 138 | 57 |
| Tramadol Hcl | Tramadol Hcl | 126 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 109 | 48 |
| Losartan Potassium | Losartan Potassium | 100 | 54 |
| Donepezil Hcl | Donepezil Hcl | 88 | 38 |
| Eliquis | Apixaban | 88 | 21 |
| Prednisone | Prednisone | 85 | 59 |
| Ozempic | Semaglutide | 73 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 31 |
| Potassium Chloride | Potassium Chloride | 71 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 36 |
| Clonazepam | Clonazepam | 69 | 18 |
| Nuplazid | Pimavanserin Tartrate | 67 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 25 |
| Famotidine | Famotidine | 65 | 30 |
| Venlafaxine Hcl | Venlafaxine Hcl | 64 | 26 |
| Montelukast Sodium | Montelukast Sodium | 62 | 27 |
| Memantine Hcl | Memantine Hcl | 60 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 58 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 58 | 28 |
| Buspirone Hcl | Buspirone Hcl | 47 | 11 |
| Mounjaro | Tirzepatide | 47 | 15 |
| Azithromycin | Azithromycin | 46 | 34 |
| Omeprazole | Omeprazole | 46 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 12 |
| Sertraline Hcl | Sertraline Hcl | 44 | 17 |
| Lisinopril | Lisinopril | 42 | 19 |
| Meloxicam | Meloxicam | 42 | 17 |
| Pregabalin | Pregabalin | 40 | 13 |
| Furosemide | Furosemide | 38 | 16 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Torsemide | Torsemide | 37 | 24 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Metformin Hcl | Metformin Hcl | 36 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 20 |
| Propranolol Hcl | Propranolol Hcl | 33 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 19 |
| Ramelteon | Ramelteon | 33 | 23 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | 11 |
| Telmisartan | Telmisartan | 31 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | 14 |
| Alendronate Sodium | Alendronate Sodium | 29 | 11 |
| Naproxen | Naproxen | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 24 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | 11 |
| Cefdinir | Cefdinir | 28 | 26 |
| Estradiol | Estradiol | 27 | 20 |
| Finasteride | Finasteride | 26 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | 12 |
| Azelastine Hcl | Azelastine Hcl | 24 | 14 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | 11 |
| Spironolactone | Spironolactone | 24 | 12 |
| Allopurinol | Allopurinol | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | 16 |
| Carvedilol | Carvedilol | 22 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 22 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | 14 |
| Buprenorphine | Buprenorphine | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Clonidine | Clonidine | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 14 |
| Bumetanide | Bumetanide | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 13 |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 13 |
| Alprazolam | Alprazolam | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,141.61 · 49 records | ACADIA Pharmaceuticals Inc | AMYVID, EVENITY, GVOKE HYPOPEN, INGREZZA, INPEN SMART INSULIN DELIVERY SYSTEM, KISUNLA, Kerendia, Korlym, NUPLAZID, Ozempic, PROLIA, QUTENZA, RECORLEV, REXULTI, Tymlos, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error